Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study.

Abstract

INTRODUCTION:

In non-cystic fibrosis (CF) bronchiectasis, the chronic airways infection is a risk factor for frequent infectious exacerbations and for an overall poor disease prognosis. Its therapy with inhaled antibiotics might be useful alike in the case of the CF-related disease.

AREAS COVERED:

Analysis and discussion of the results of a Phase II study evaluating the efficacy and safety of the inhaled ciprofloxacin-dry powder (C-DPI) formulation in patients with non-CF bronchiectasis.

EXPERT OPINION:

On short-term basis C-DPI is able to reduce the sputum bacterial load in such patients but long-term studies are also needed to better characterize the clinical efficacy of this compound.

• Authors: Sabina Antoniu, Doina Azoicai
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 22 Issue 5 Pg. 671-3 (May 2013) ISSN: 1744-7658 [Electronic] England
• PMID: 23516961 (Publication Type: Journal Article)